March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
A 6-Month, Observational Trial Investigating with Electronic Monitoring the Level of Adherence and Ocular Surface Health with Latanoprost/Timolol Fixed Versus Latanoprost and Timolol Unfixed Therapy in Glaucoma
Author Affiliations & Notes
  • Kostas G. Boboridis
    1st Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Anastasios G. Konstas
    1st Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Victoria Toumanidou
    1st Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Antony T. Dimopoulos
    1st Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Dimitrios G. Mikropoulos
    1st Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • George Moumtzis
    1st Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Theodoros Giannopoulos
    1st Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Irini C. Voudouragkaki
    1st Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Eleni Paschalinou
    1st Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Malik Y. Kahook
    Ophthalmology, University of Colorado, Aurora, Colorado
  • Footnotes
    Commercial Relationships  Kostas G. Boboridis, Alcon, Allergan, MSD (R); Anastasios G. Konstas, Alcon, Allergan, MSD (C), Alcon, Allergan, MSD, Pfizer (R); Victoria Toumanidou, None; Antony T. Dimopoulos, None; Dimitrios G. Mikropoulos, None; George Moumtzis, None; Theodoros Giannopoulos, None; Irini C. Voudouragkaki, None; Eleni Paschalinou, None; Malik Y. Kahook, Alcon, Merck, Allergan, Glaukos, Ivantis (C), Alcon,Merck, Allergan, Genentech, Actelion, Glaukos (R)
  • Footnotes
    Support  Pfizer
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5097. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kostas G. Boboridis, Anastasios G. Konstas, Victoria Toumanidou, Antony T. Dimopoulos, Dimitrios G. Mikropoulos, George Moumtzis, Theodoros Giannopoulos, Irini C. Voudouragkaki, Eleni Paschalinou, Malik Y. Kahook; A 6-Month, Observational Trial Investigating with Electronic Monitoring the Level of Adherence and Ocular Surface Health with Latanoprost/Timolol Fixed Versus Latanoprost and Timolol Unfixed Therapy in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5097.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate, for the first time, the impact of dosing upon the rate of adherence and ocular surface health comparing fixed versus concomitant unfixed treatment in glaucoma.

Methods: : Prospective 6-month, parallel, observational study. We recruited well controlled patients with open-angle glaucoma or ocular hypertension who received either unfixed therapy comprising Latanoprost (Xalatan) once in the evening and Timolol twice daily, or Latanoprost/Timolol Fixed Combination (Xalacom) therapy once in the evening. We investigated the level of adherence and selected signs of ocular surface disease (OSD) in the two groups at baseline and after 3 and 6 months of follow up. All eligible patients who consented were recruited and their adherence was monitored with the MEMS Caps device. Morning IOP control, rate of adherence (% of doses instilled), and signs of OSD were compared between groups.

Results: : One hundred-forty-two consecutive patients (71 in the fixed and 71 in the unfixed group) were enrolled and evaluated in the present study. There were no baseline differences between the two groups with regard to age, sex, diagnosis, duration of therapy, visual acuity and corneal thickness. Patients in the unfixed group however demonstrated worse vertical cup-to-disc ratio (0.65 vs 0.58, P=0.005) and worse mean visual field defect (5,9 vs 3,8 dB, P=0.017) at baseline. Mean morning IOP was similar between groups at baseline, 1 and 3 months but the unfixed group demonstrated higher mean IOP at 6 months (16.6 vs 15.0 mm Hg, P=0.009). Adherence rate, was significantly better in the fixed combination group at 3 (75.6% vs 61.2%) and 6 months (73.0% vs 57.3%) of follow up (P=0.001 for both comparisons). Signs of OSD (Break Up Time, Schirmer test, corneal and conjunctival staining,) were significantly worse in the unfixed group at baseline and for every subsequent evaluation (P<0.01 for all comparison).

Conclusions: : This trial demonstrated significantly superior rate of adherence and ocular surface health in the fixed combination treatment group. Therefore we observed a negative impact upon adherence and ocular surface health from multiple dosing (three-times-daily) in patients with open-angle glaucoma, or ocular hypertension. This trial provides for the first time verification for the benefits accrued in terms of adherence and ocular surface health with fixed combination therapy.

Clinical Trial: : http://www.clinicaltrials.gov NCT 01281020

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • cornea: clinical science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×